Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Current Liabilities (2016 - 2025)

Ascendis Pharma A's Total Current Liabilities history spans 8 years, with the latest figure at $792.4 million for Q4 2023.

  • For Q4 2023, Total Current Liabilities rose 353.5% year-over-year to $792.4 million; the TTM value through Dec 2023 reached $792.4 million, up 353.5%, while the annual FY2023 figure was $796.7 million, 341.35% up from the prior year.
  • Total Current Liabilities for Q4 2023 was $792.4 million at Ascendis Pharma A, up from $174.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $792.4 million in Q4 2023 and bottomed at $53.1 million in Q4 2019.
  • The 5-year median for Total Current Liabilities is $114.8 million (2021), against an average of $239.6 million.
  • The largest annual shift saw Total Current Liabilities rose 18.52% in 2020 before it surged 353.5% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $53.1 million in 2019, then increased by 18.52% to $63.0 million in 2020, then surged by 82.35% to $114.8 million in 2021, then surged by 52.21% to $174.7 million in 2022, then soared by 353.5% to $792.4 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Total Current Liabilities are $792.4 million (Q4 2023), $174.7 million (Q4 2022), and $114.8 million (Q4 2021).